Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
Clinical trial NCT07292207 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07292207
- Sponsor
- Nagoya City University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-10
- Primary completion
- 2028-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.